BioCentury
ARTICLE | Strategy

Streamlining Takeda's Profit Story

Takeda needs to execute on cost-cutting, pipeline to meet EPS expectations

October 13, 2014 7:00 AM UTC

After spending a decade growing the company via acquisition, Takeda Pharmaceutical Co. Ltd. is now focused on getting its costs in line with its global pharma peers. But to grow EPS in line with Street expectations, the pharma also will have to hit its existing pipeline on all cylinders.

New president Christophe Weber's predictable first move since taking the operational helm appears to be a continued implementation of cost-cutting plans that were unveiled before he joined Takeda in April...